This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01251/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01251/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01251/identifier/pubchem-compound/
n14http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB01251/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01251/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01251/identifier/drugbank/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01251/identifier/chemspider/
n18http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01251
rdf:type
n3:Drug
n3:description
Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
n3:group
approved
n3:halfLife
The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours)
n3:indication
Used in the treatment of diabetes mellitus type 2.
owl:sameAs
n8:DB01251 n14:DB01251
dcterms:title
Gliquidone
adms:identifier
n6:Gliquidone n9:PA164744895 n10:46508425 n11:D02430 n12:91610 n13:82719 n15:DB01251
n3:mechanismOfAction
The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
n3:synonym
Glurenorm
n3:synthesisReference
U.S. Patent 3,708,486.
n3:IUPAC-Name
n4:271B5F31-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5F37-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5F36-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5F33-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5F34-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5F35-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5F2F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5F48-363D-11E5-9242-09173F13E4C5 n4:271B5F2D-363D-11E5-9242-09173F13E4C5 n4:271B5F30-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5F2E-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:A10BB08
n3:H-Bond-Acceptor-Count
n4:271B5F3D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5F3E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5F38-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5F39-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5F3B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5F3A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5F3C-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
33342-05-1
n3:category
n3:Bioavailability
n4:271B5F43-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5F45-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5F46-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5F47-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5F42-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5F41-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5F44-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5F32-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5F3F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5F40-363D-11E5-9242-09173F13E4C5